| Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in … RR Bahadoer, EA Dijkstra, B van Etten, CAM Marijnen, H Putter, ... The Lancet Oncology 22 (1), 29-42, 2021 | 1745 | 2021 |
| Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a … RK Kelley, M Ueno, C Yoo, RS Finn, J Furuse, Z Ren, T Yau, HJ Klümpen, ... The Lancet 401 (10391), 1853-1865, 2023 | 965 | 2023 |
| Rectal and colon cancer: Not just a different anatomic site K Tamas, AME Walenkamp, EGE De Vries, M Van Vugt, RG Beets-Tan, ... Cancer treatment reviews 41 (8), 671-679, 2015 | 406 | 2015 |
| A review of bispecific antibodies and antibody constructs in oncology and clinical challenges FV Suurs, MN Lub-de Hooge, EGE de Vries, DJA de Groot Pharmacology & therapeutics 201, 103-119, 2019 | 369 | 2019 |
| The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs DL van der Velden, LR Hoes, H van der Wijngaart, ... Nature 574 (7776), 127-131, 2019 | 285 | 2019 |
| Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer–Results of the international randomized … MJM van der Valk, CAM Marijnen, B van Etten, EA Dijkstra, DE Hilling, ... Radiotherapy and Oncology 147, 75-83, 2020 | 235 | 2020 |
| Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic DJA De Groot, EGE De Vries, HJM Groen, S De Jong Critical reviews in oncology/hematology 61 (1), 52-69, 2007 | 233 | 2007 |
| Theranostics using antibodies and antibody-related therapeutics KL Moek, D Giesen, IC Kok, DJA de Groot, M Jalving, RSN Fehrmann, ... Journal of Nuclear Medicine 58 (Supplement 2), 83S-90S, 2017 | 129 | 2017 |
| Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial L Kist de Ruijter, PP van de Donk, JS Hooiveld-Noeken, D Giesen, ... Nature Medicine 28 (12), 2601-2610, 2022 | 114 | 2022 |
| Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal … KP Rovers, C Bakkers, GAAM Simkens, JWA Burger, SW Nienhuijs, ... Bmc Cancer 19 (1), 390, 2019 | 108 | 2019 |
| Molecular imaging biomarkers for immune checkpoint inhibitor therapy PP van de Donk, LK de Ruijter, MN Lub-de Hooge, AH Brouwers, ... Theranostics 10 (4), 1708, 2020 | 102 | 2020 |
| 89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer IC Kok, JS Hooiveld, PP van de Donk, D Giesen, EL van der Veen, ... Annals of Oncology 33 (1), 80-88, 2022 | 98 | 2022 |
| Proteasome inhibitor MG132 sensitizes HPV‐positive human cervical cancer cells to rhTRAIL‐induced apoptosis BMT Hougardy, JH Maduro, AGJ van der Zee, DJA de Groot, ... International journal of cancer 118 (8), 1892-1900, 2006 | 95 | 2006 |
| Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition RRH van den Brom, WH Abdulahad, A Rutgers, BJ Kroesen, ... Rheumatology 55 (6), 1143-1145, 2016 | 84 | 2016 |
| Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1 DJA De Groot, M Van Der Deen, TKP Le, A Regeling, S De Jong, ... British journal of cancer 97 (8), 1077-1083, 2007 | 75 | 2007 |
| The antibody–drug conjugate target landscape across a broad range of tumour types KL Moek, DJA de Groot, EGE de Vries, RSN Fehrmann Annals of Oncology 28 (12), 3083-3091, 2017 | 68 | 2017 |
| Perioperative systemic therapy vs cytoreductive surgery and hyperthermic intraperitoneal chemotherapy alone for resectable colorectal peritoneal metastases: A phase 2 … KP Rovers, C Bakkers, SW Nienhuijs, JWA Burger, GJM Creemers, ... JAMA surgery 156 (8), 710-720, 2021 | 65 | 2021 |
| Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy PA Boonstra, TT Wind, M van Kruchten, E Schuuring, GAP Hospers, ... Cancer and Metastasis Reviews 39 (3), 999-1013, 2020 | 65 | 2020 |
| Patients with rare cancers in the drug rediscovery protocol (DRUP) benefit from genomics-guided treatment LR Hoes, JM van Berge Henegouwen, H van der Wijngaart, LJ Zeverijn, ... Clinical Cancer Research 28 (7), 1402-1411, 2022 | 63 | 2022 |
| Glypican 3 overexpression across a broad spectrum of tumor types discovered with functional genomic mRNA profiling of a large cancer database KL Moek, RSN Fehrmann, B van der Vegt, EGE de Vries, DJA de Groot The American journal of pathology 188 (9), 1973-1981, 2018 | 57 | 2018 |
Elisabeth de VriesProfessor of Medical Oncology, University Medical Center Groningen, Groningen, the NetherlandsVerified email at umcg.nl
